Form 4: Jazz Pharma Director's Stock Activity

Jazz Pharmaceuticals director Kenneth W. O'Keefe reported the acquisition of restricted stock units and the sale of shares to cover tax obligations.

Summary

• Director Kenneth W. O'Keefe reported changes in beneficial ownership of Jazz Pharmaceuticals plc ordinary shares.
• On August 7, 2025, O'Keefe acquired 3,507 restricted stock units (RSUs) under the Issuer's 2007 Amended and Restated Non-Employee Directors Stock Award Plan.
• Each RSU represents a contingent right to receive one ordinary share upon vesting, which is scheduled for July 24, 2026, subject to continuous service.
• On August 8, 2025, O'Keefe disposed of 1,805 ordinary shares at a price of $111.2502 per share.
• This disposition was specifically to satisfy tax obligations arising from the vesting of previously granted restricted stock units.
• Following these transactions, O'Keefe directly holds 28,672 ordinary shares and indirectly holds 4,445 ordinary shares through The Kenneth W. O'Keefe Trust.

Sentiment

Score: 5

Explanation: The filing details routine insider transactions involving equity compensation and tax-related share sales, which are standard occurrences and do not indicate a significant positive or negative shift in company outlook.

Positives

• The acquisition of 3,507 restricted stock units aligns the director's interests with long-term company performance and shareholder value.

Negatives

• The disposition of 1,805 ordinary shares, although for tax purposes, reduces the director's direct ownership stake in the company.

Future Outlook

The 3,507 restricted stock units acquired are scheduled to vest in full on July 24, 2026, contingent on the reporting person's continuous service and certain additional conditions.

Industry Context

This Form 4 filing details routine insider transactions, which are common occurrences for publicly traded companies as part of executive and director compensation plans. Such filings provide transparency into insider holdings but typically do not reflect broader industry trends or competitive shifts.

Related Party Transactions

• 4,445 ordinary shares are held indirectly for the benefit of The Kenneth W. O'Keefe Trust U/A/D 2/12/1997, of which the reporting person is both trustee and beneficiary.

Stakeholder Impact

• Shareholders: Minimal direct impact as these are routine insider transactions related to compensation and tax obligations, not indicative of a change in company fundamentals.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of 3,507 restricted stock units on July 24, 2026.

Key Dates

Recommendation

This Form 4 filing details routine insider stock transactions, specifically the grant of restricted stock units as part of director compensation and the subsequent sale of shares to cover tax obligations. Such transactions are common and do not typically signal a change in the company's fundamental prospects or warrant a change in investment recommendation. The core business operations and financial health of Jazz Pharmaceuticals plc remain the primary drivers for investment decisions.

Keywords

Jazz Pharmaceuticals, JAZZ, Form 4, Insider Trading, Stock Ownership, Director, Kenneth O'Keefe, Restricted Stock Units, RSU, Share Sale, Tax Obligations